DC Chemicals received good feedback from our customers.
MORE>>Featured Products
Cat. No. Product name CAS No.
DC53045 STM2457 Featured

STM2457 is in stock, and we can ship it immeidately. STM2457 is a potent inhibitor of METTL3/METTL14 catalytic activity with IC50 of 16.9 nM, Kd of 1.4 nM, respectively. STM2457 is highly specific for METTL3 and shows significant anti-leukaemic effect.

DC39817 LDC203974(IMT1B) Featured

LDC203974(IMT1B) is a highly specific inhibitor of human mitochondrial RNA polymerase (POLRMT) with improved pharmacokinetic profiles than LDC195943(IMT1).

DC39031 MSA-2 Featured

MSA-2 is an orally available human STING agonist.MSA-2 is bound to STING as a noncovalent dimer. Extensive experimental analysis indicates that MSA-2 predimerization is required for binding. Acidic tumor microenvironments favor permeable, uncharged MSA-2. Intracellular MSA-2 is "trapped" and accumulation drives MSA-2 dimerization, preferentially activating STING intratumorally. Orally dosed MSA-2 is well tolerated in mice, exhibiting STING-dependent antitumor activity, as monotherapy and combined with antibodies against PD1 (anti-PD1).

DC39024 AT-527 Featured

AT-527, a hemisulfate salt of AT-511, a guanosine nucleotide prodrug, is a potent and orally active HCV viral replication inhibitor. AT-527 is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). AT-527 has pangenotypic antiviral activity[1][2][3].AT-511 has pan-genotypic antiviral activities that inhibits HCV genotype 1a (HCV GT1a), HCV GT1b, HCV GT2a, HCV GT3a, HCV GT4a, and HCV GT5a replication with EC50 values of 12.8 nM, 12.5 nM, 9.2 nM, 10.3 nM, 14.7 nM, and 28.5 nM, respectively[1]. In normal human airway epithelial cells, the concentration of AT-511 required to inhibit replication of SARS-CoV-2 by EC90 is 0.47 μM, very similar to its EC90 against HCoV-229E, HCoV-OC43 and SARS-CoV in Huh-7 cells[2].

DC27035 EIDD-2801(Molnupiravir) Featured

Molnupiravir, also known as EIDD-2801 and MK-4482, is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. EIDD-2801 is a prodrug of EIDD-1931.

DC26136 MRTX849(Adagrasib) Featured

MRTX849(Adagrasib) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. MRTX849 covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction[1][2].

DC10800 DLin-MC3-DMA Featured

D-Lin-MC3-DMA(MC3) is the most potent cationic lipid that has been synthesized for Lipid nanoparticles (LNPs) to deliver the siRNA.

DC7460 Masitinib Featured

Masitinib is a broad coronavirus 3CL inhibitor that effectively blocks replication of SARS-CoV-2. Science 20 Jul 2021: eabg5827 DOI: 10.1126/science.abg5827

DC1023 CHIR-99021 (CT99021) Featured

CHIR-99021 is a glycogen synthase kinase 3 beta inhibitor that has antiproliferative activity in vitro and in vivo.

DC21382 EIDD-1931(NHC) Featured

EIDD-1931 (β-d-N4-Hydroxycytidine, NHC) inhibits both murine hepatitis virus (MHV) (EC50 of 0.17 μM) and Middle East respiratory syndrome CoV (MERS-CoV) (EC50 of 0.56 μM) with minimal cytotoxicity. It also inhibits SARS-CoV-2 and multiple 2 endemic, epidemic and bat coronavirus.